Laboratory Co. of America (LH) Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Laboratory Co. of America in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LH shares.
View LH analyst ratings or view top-rated stocks.

9 Wall Street research analysts have issued 1 year price targets for Laboratory Co. of America's shares. Their LH share price forecasts range from $235.00 to $303.00. On average, they expect the company's stock price to reach $273.50 in the next twelve months. This suggests a possible upside of 26.0% from the stock's current price.
View analysts price targets for LH or view top-rated stocks among Wall Street analysts.

Laboratory Co. of America's stock was trading at $235.48 at the beginning of 2023. Since then, LH shares have decreased by 7.9% and is now trading at $216.98.
View the best growth stocks for 2023 here.

Laboratory Co. of America saw a increase in short interest in April. As of April 30th, there was short interest totaling 1,810,000 shares, an increase of 10.4% from the April 15th total of 1,640,000 shares. Based on an average trading volume of 616,300 shares, the days-to-cover ratio is presently 2.9 days. Approximately 2.1% of the company's shares are short sold.
View Laboratory Co. of America's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 27th 2023.
View our LH earnings forecast.

Laboratory Co. of America Holdings (NYSE:LH) posted its quarterly earnings results on Tuesday, April, 25th. The medical research company reported $3.82 earnings per share for the quarter, missing the consensus estimate of $3.99 by $0.17. The medical research company earned $3.78 billion during the quarter, compared to analyst estimates of $3.70 billion. Laboratory Co. of America had a trailing twelve-month return on equity of 15.56% and a net margin of 6.78%. The business's revenue was down 3.1% on a year-over-year basis. During the same period in the previous year, the company posted $6.11 EPS.
Read the conference call transcript.

Laboratory Co. of America declared a quarterly dividend on Thursday, April 6th. Investors of record on Thursday, May 18th will be given a dividend of $0.72 per share on Thursday, June 8th. This represents a $2.88 annualized dividend and a yield of 1.33%. The ex-dividend date is Wednesday, May 17th.
Read our dividend analysis for LH.

ETFs with the largest weight of Laboratory Co. of America (NYSE:LH) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), Global X Telemedicine & Digital Health ETF (EDOC), iShares U.S. Healthcare Providers ETF (IHF), Hennessy Stance ESG Large Cap ETF (STNC), VictoryShares THB Mid Cap ESG ETF (MDCP), First Trust Health Care AlphaDEX Fund (FXH), Thrivent Small-Mid Cap ESG ETF (TSME) and SEI Enhanced U.S. Large Cap Value Factor ETF (SEIV).

Laboratory Co. of America (NYSE:LH) pays an annual dividend of $2.88 per share and currently has a dividend yield of 1.33%. The dividend payout ratio is 26.13%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, LH will have a dividend payout ratio of 15.75% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for LH.

Laboratory Co. of America issued an update on its FY 2023 earnings guidance on Thursday, April, 27th. The company provided earnings per share guidance of $16.25-$17.75 for the period, compared to the consensus estimate of $17.17. The company issued revenue guidance of -.

143 employees have rated Laboratory Co. of America Chief Executive Officer Adam Schechter on Glassdoor.com. Adam Schechter has an approval rating of 73% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Laboratory Co. of America investors own include Gilead Sciences (GILD), Micron Technology (MU), Intel (INTC), Pfizer (PFE), Johnson & Johnson (JNJ), NVIDIA (NVDA), Abbott Laboratories (abt), AbbVie (ABBV), Alibaba Group (BABA) and Amgen (AMGN).

Laboratory Co. of America trades on the New York Stock Exchange (NYSE) under the ticker symbol "LH."

Laboratory Co. of America's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (13.50%), State Street Corp (4.44%), Wellington Management Group LLP (3.05%), Geode Capital Management LLC (2.08%), Dimensional Fund Advisors LP (1.67%) and FMR LLC (1.14%). Insiders that own company stock include Amy B Summy, Brian J Caveney, Der Vaart Sandra D Van, Dwight Gary Gilliland, Glenn A Eisenberg, Jean-Luc Belingard, Mark S Schroeder, Paul R Kirchgraber, Peter J Wilkinson, Peter M Neupert and R Sanders Williams.
View institutional ownership trends.

Shares of LH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LH stock can currently be purchased for approximately $216.98.

Laboratory Co. of America (NYSE:LH) has a market capitalization of $19.22 billion and generates $14.88 billion in revenue each year. The medical research company earns $1.28 billion in net income (profit) each year or $11.02 on an earnings per share basis.

The company employs 80,000 workers across the globe.

Laboratory Co. of America's mailing address is 358 South Main Street, BURLINGTON NC, 27215. The official website for the company is www.labcorp.com. The medical research company can be reached via phone at (336) 229-1127, via email at investor@labcorp.com, or via fax at 336-513-4510.